Objective: To evaluate objectively the effectiveness and safety of intergration of Zhengqing Fengtongning and methotrexate on treatment of rheumatoid arthritis. Method: Sesrching pubished literature database through Vip

CNKI

Wanfang

CMCI＼CMCC

MEDLINE

Science Direct

and SpringerLink Resources;'rheumatoid arthritis’'arthritis’ 'rheuma-toid diseases’as index terms.Randomized controled trail on treatment of rheumatoid arthritis by intergration of Zhengqing Fengtongning and methotrexate on treatment of rheumatoid arthritis was taken as object of study

statistical analysis was carried on through Rev-Man 5.0 software offered by Cochrane. Result: The total enrolled number of patiens is 735 in 8 randomized controlled trials(RCT). The raise rate of each focus poinr is total effective [MD0.31

95%CI(0.18

0.52) P<0.000 1];Morning stiff[MD-29.66

95%CI(-36.86

-22.4)

P<0.000 01];erythrocyle sedimentation rate (ESR)[MD-4.87

95%CI(-6.66

-3.08)

P<0.000 01]; rheumatoid factor(RF)[MD16.29

95%CI(14.71

17.88)

P<0.000 01];CRP[MD-3.88

95%CI(-4.69

-3.06)

P<0.000 01]. Conclusion: The results of this system review show that the intergration of Zhengqing Fengtongning and methotrexate can improve the sign and laboratory indexes and much better than that of methotrexate alone on rheumatoid arthrtis.At the same time

it reduce adverse effects.